Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU

86
18
Favorite

Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU

T-Reuters2022-02-16

OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

mubin
·2022-02-16
👍
Reply
Like
Report
Goodytrader
·2022-02-16
Wooo
Reply
Like
Report
Grednana
·2022-02-16
👍
Reply
Like
Report
Jess261
·2022-02-16
Okay
Reply
1
Report
TK360
·2022-02-16
Nice
Reply
1
Report
lewisleeks
·2022-02-16
Great 👍
Reply
Like
Report
Ahdesfrmsg
·2022-02-16
Ok
Reply
1
Report
AA23
·2022-02-16
Ok
Reply
1
Report
Ryanlmh
·2022-02-16
K
Reply
2
Report
leeinvest
·2022-02-16
...
Reply
1
Report
慧茴
·2022-02-16
Ok
Reply
3
Report
Gladys8jk
·2022-02-16
Ok
Reply
3
Report
74rk
·2022-02-16
what
Reply
4
Report
Wenikho
·2022-02-16
Ok
Reply
4
Report
JaiVenky
·2022-02-16
Nice
Reply
5
Report
SherryVJ
·2022-02-16
Wow
Reply
3
Report
Scarface
·2022-02-16
[NosePick]
Reply
5
Report
9448Huat
·2022-02-16
Good news👍
Reply
8
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2211631331?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-16 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2211631331","market":"us","top_or_hot":-1,"title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","media":"T-Reuters","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 00:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.trkd.thomsonreuters.com><strong>T-Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - ...</p>\n\n<a href=\"https://www.trkd.thomsonreuters.com\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://www.trkd.thomsonreuters.com","article_id":"2211631331","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","pubTimestamp":1644941342,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药"},"translate_title":"辉瑞和OPKO每周一次的Ngenla注射液在欧盟获得上市授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":9095475381,"gmtCreate":1644980592752,"gmtModify":1676533983157,"author":{"id":"3584152701479685","authorId":"3584152701479685","name":"mubin","avatar":"https://community-static.tradeup.com/news/2f4144cf2b92967947571c6290ec8901","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584152701479685","idStr":"3584152701479685"},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095475381","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095466444,"gmtCreate":1644974709349,"gmtModify":1676533982037,"author":{"id":"3576558112374517","authorId":"3576558112374517","name":"Goodytrader","avatar":"https://static.tigerbbs.com/de4ed05450299b7dbc3a7c9c2a232555","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3576558112374517","idStr":"3576558112374517"},"htmlText":"Wooo","listText":"Wooo","text":"Wooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095466444","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095466052,"gmtCreate":1644974605163,"gmtModify":1676533982045,"author":{"id":"3571355542071247","authorId":"3571355542071247","name":"Grednana","avatar":"https://static.tigerbbs.com/aff5083a5c5c5db47d53e17857443b44","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3571355542071247","idStr":"3571355542071247"},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095466052","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095481931,"gmtCreate":1644973159065,"gmtModify":1676533981749,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3586490638953193","idStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095481931","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095433654,"gmtCreate":1644971118588,"gmtModify":1676533981188,"author":{"id":"3574766349354741","authorId":"3574766349354741","name":"TK360","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3574766349354741","idStr":"3574766349354741"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095433654","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095400874,"gmtCreate":1644968853105,"gmtModify":1676533980620,"author":{"id":"4089010444435920","authorId":"4089010444435920","name":"lewisleeks","avatar":"https://static.tigerbbs.com/d39cf835a09bdd21dce8a780b993940c","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"4089010444435920","idStr":"4089010444435920"},"htmlText":"Great 👍&nbsp;","listText":"Great 👍&nbsp;","text":"Great 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095400874","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095545361,"gmtCreate":1644967766300,"gmtModify":1676533980305,"author":{"id":"4091358583248150","authorId":"4091358583248150","name":"Ahdesfrmsg","avatar":"https://static.tigerbbs.com/1c7beb9d76c8c0b998733ae7bb8974d8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"4091358583248150","idStr":"4091358583248150"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095545361","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095528072,"gmtCreate":1644965386780,"gmtModify":1676533979642,"author":{"id":"4098879381617960","authorId":"4098879381617960","name":"AA23","avatar":"https://static.tigerbbs.com/e6d21140696c12bece250857ee21bd8f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"4098879381617960","idStr":"4098879381617960"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095528072","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095566552,"gmtCreate":1644964282710,"gmtModify":1676533979456,"author":{"id":"3578957745184735","authorId":"3578957745184735","name":"Ryanlmh","avatar":"https://static.tigerbbs.com/324c4246e253d95bc0bd401464a399c1","vip":1,"crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3578957745184735","idStr":"3578957745184735"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095566552","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095563457,"gmtCreate":1644963934737,"gmtModify":1676533979201,"author":{"id":"4099790386907850","authorId":"4099790386907850","name":"leeinvest","avatar":"https://static.tigerbbs.com/b480051f839130f7274379fc24924fd2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4099790386907850","idStr":"4099790386907850"},"htmlText":"...","listText":"...","text":"...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095563457","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095587593,"gmtCreate":1644963625926,"gmtModify":1676533979133,"author":{"id":"4099365134782650","authorId":"4099365134782650","name":"慧茴","avatar":"https://community-static.tradeup.com/news/ee07658a2ed77fd4618d0ed2b3e64e40","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4099365134782650","idStr":"4099365134782650"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095587593","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095587384,"gmtCreate":1644963575948,"gmtModify":1676533979118,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4094787128284850","idStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095587384","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095514284,"gmtCreate":1644960655006,"gmtModify":1676533978872,"author":{"id":"3584006131453100","authorId":"3584006131453100","name":"74rk","avatar":"https://static.tigerbbs.com/5d2cbf8ec63fa4fc1ffb7189ba15e1bc","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584006131453100","idStr":"3584006131453100"},"htmlText":"what","listText":"what","text":"what","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095514284","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095510930,"gmtCreate":1644950301205,"gmtModify":1676533978668,"author":{"id":"3583735307988740","authorId":"3583735307988740","name":"Wenikho","avatar":"https://static.tigerbbs.com/48d673eefef20f75808048d78501a48f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583735307988740","idStr":"3583735307988740"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095510930","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095538869,"gmtCreate":1644945402907,"gmtModify":1676533978363,"author":{"id":"3585210617348402","authorId":"3585210617348402","name":"JaiVenky","avatar":"https://static.tigerbbs.com/097793f3135b5fb8cb3f03847d72bf1a","vip":1,"crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3585210617348402","idStr":"3585210617348402"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095538869","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095594964,"gmtCreate":1644942960488,"gmtModify":1676533978240,"author":{"id":"3586426326873853","authorId":"3586426326873853","name":"SherryVJ","avatar":"https://community-static.tradeup.com/news/1881722e980e541f3c66ed217d5b91c6","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3586426326873853","idStr":"3586426326873853"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095594964","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095592109,"gmtCreate":1644942369541,"gmtModify":1676533978209,"author":{"id":"3560993393373290","authorId":"3560993393373290","name":"Scarface","avatar":"https://community-static.tradeup.com/news/ecc3b3fda33ad81dbec4b8a8bf80311a","vip":1,"crmLevel":1,"crmLevelSwitch":1,"authorIdStr":"3560993393373290","idStr":"3560993393373290"},"htmlText":"[NosePick]&nbsp;","listText":"[NosePick]&nbsp;","text":"[NosePick]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095592109","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095598493,"gmtCreate":1644942103115,"gmtModify":1676533978154,"author":{"id":"3578031300804164","authorId":"3578031300804164","name":"9448Huat","avatar":"https://static.tigerbbs.com/bc2263efe7491ac00986db5a83b7ce8c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3578031300804164","idStr":"3578031300804164"},"htmlText":"Good news👍","listText":"Good news👍","text":"Good news👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095598493","repostId":2211631331,"repostType":2,"repost":{"id":"2211631331","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1644941342,"share":"https://ttm.financial/m/news/2211631331?lang=&edition=fundamental","pubTime":"2022-02-16 00:09","market":"us","language":"en","title":"Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631331","media":"T-Reuters","summary":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Aut","content":"<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer And Opko’S Once-Weekly Ngenla Injection Receives Marketing Authorization In EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-02-16 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>OPKO Health Inc <opk.o>:Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.<a href=\"https://laohu8.com/S/OPK\">Opko Health</a> Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.</opk.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4007":"制药","BK4534":"瑞士信贷持仓"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2211631331","content_text":"OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":86,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}